A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
study id #: NCT06260709
condition: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
status: Recruiting
purpose:This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called “A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis”. Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for up to 157 weeks (36 months/3 years).
intervention: NNC6019-0001
results: https://clinicaltrials.gov/ct2/show/results/NCT06260709
last updated: March 10, 2024
-
Jeffrey Zonder, MDDr. Zonder is a Clinical Professor at De...
-
Ute HegenbartUte Hegenbart is a Senior Physician and ...
-
ATTR in the Heart – ASG Webinar 1/7https://www.youtube.com/watch?v=IzC_yaqs...
-
Pitfalls in Conducting Prospective Trials in Stage III Cardiac Amyloidosis – Experience from the REVEAL StudyVery few prospective clinical trials hav...
-
Karmanos Cancer InstituteKarmanos Cancer Institute, headquartered...
-
Anne Marie CarrMy name is Anne Marie Carr and I was dia...
-
New and Developing Therapies for AL AmyloidosisSystemic light-chain (AL) amyloidosis is...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.